Table 4.
FcγRIIA-131His/Arg, FcγRIIIA-176F/V and FcγRIIIB-NA1/NA2 haplotypes | Study groups | P-value* | SMA (Hb < 6.0 g/dL | |||
---|---|---|---|---|---|---|
SMA n (%) |
non-SMA n (%) |
OR | 95% CI | P-value** | ||
131Arg/176F/NA2 (n = 171) | 79 (69.3) | 92 (57.5) | 0.044 | 1.70 | 1.02–2.93 | 0.036 |
131His/176F/NA1 (n = 59) | 30 (26.3) | 29 (18.1) | 0.104 | 1.80 | 0.98–3.30 | 0.057 |
131His/176F/NA2 (n = 87) | 32 (28.1) | 55 (34.4) | 0.269 | 0.76 | 0.44–1.32 | 0.334 |
131His/176 V/NA1 (n = 79) | 28 (24.6) | 51 (31.9) | 0.188 | 0.71 | 0.41–1.25 | 0.234 |
Children with acute malaria (n = 274) were grouped based on SMA (defined as Hb < 6.0 g/dL, with any density parasitemia) [25]. Odds ratios (OR) and 95% confidence intervals (CI) were determined using bivariate logistic regression controlling for age, gender, co-infections (HIV-1 and bacteremia) sickle cell trait (HbAS), alpha-thalassemia and G6PD deficiency. The reference groups in the regression analysis were the non-carriage of respective haplotypic structures. n; the number of participants with the respective haplotype. n (%); number (percentage) of participants with respective haplotype in each study group. *P-value determined using Chi-square (χ2). **P-values determined using logistics regression analysis. All P-values were considered statistically significant at P ≤ 0.05
Values in bold are significant p-values at a cut-off of p≤0.05